DBPR-110
| Code | Size | Price |
|---|
| TAR-T27125-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
DBPR-110 is a nonstructural protein 5A (NS5A) inhibitor. DBPR-110 reduced the reporter expression of the HCV1b replicon with a EC(50) and a selective index value of 3.9 ? 0.9 pM and >12,800,000, respectively. DBPR-110 reduced HCV2a replicon activity with an EC(50) and a selective index value of 228.8 ? 98.4 pM and >173,130, respectively.
CAS:
1310694-75-7
Formula:
C50H48N6O4S2
Molecular Weight:
861.09
Purity:
0.98
SMILES:
O=C(NC(C(=O)N1CCCC1c1ncc(s1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc(s1)C1CCCN1C(=O)C(NC(=O)C1CC1)c1ccccc1)c1ccccc1)C1CC1
References
1. Lin HM, Wang JC, Hu HS, Wu PS, Wang WH, Wu SY, Yang CC, Yeh TK, Hsu TA, Jiaang WT, Chao YS, Chern JH, Yueh A. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems. Antimicrob Agents Chemother. 2013 Feb;57(2):723-33. doi: 10.1128/AAC.01403-12. PubMed PMID: 23165461; PubMed Central PMCID: PMC3553732.